RITALIN-SR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITALIN-SR is an extended-release oral tablet formulation of methylphenidate, a central nervous system stimulant approved since 1982. The mechanism of action involves inhibition of dopamine and norepinephrine reuptake, enhancing focus and attention. It is primarily indicated for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy in pediatric and adult populations.
LOE Approaching
Approaching loss of exclusivity signals need for brand defense strategies; commercial team likely transitioning from growth to retention focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers
Started May 2010
30 enrolled
Pharmacokinetics
Career Relevance
RITALIN-SR offers stability-focused career paths centered on brand defense, generic competition management, and market access strategy rather than growth-stage opportunities. Roles emphasize cost optimization, reimbursement protection, and customer retention as the product approaches loss of exclusivity.
Brand Manager
Worked on RITALIN-SR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.